Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this endpoint study is to evaluate the safety of tofacitinib at two doses versus TNFi; the co-primary endpoints are adjudicated major adverse cardiovascular events (MACE) and adjudicated malignancies excluding non-melanoma skin cancers during study participation.
Inclusion criteria
- Rheumatoid Arthritis